Your browser doesn't support javascript.
loading
Use of angiotensin converting enzyme inhibitors is associated with reduced risk of late bladder toxicity following radiotherapy for prostate cancer.
Kerns, Sarah L; Amidon Morlang, Ashley; Lee, Sharon M; Peterson, Derick R; Marples, Brian; Zhang, Hong; Bylund, Kevin; Rosenzweig, Doug; Hall, William; De Ruyck, Kim; Rosenstein, Barry S; Stock, Richard G; Gómez-Caamaño, Antonio; Vega, Ana; Sosa-Fajardo, Paloma; Taboada-Valladares, Begoña; Aguado-Barrera, Miguel E; Parker, Chris; Veldeman, Liv; Fonteyne, Valérie; Bultijnck, Renée; Talbot, Christopher J; Symonds, R Paul; Johnson, Kerstie; Rattay, Tim; Webb, Adam; Lambrecht, Maarten; de Ruysscher, Dirk; Vanneste, Ben; Choudhury, Ananya; Elliott, Rebecca M; Sperk, Elena; Herskind, Carsten; Veldwijk, Marlon R; Rancati, Tiziana; Avuzzi, Barbara; Valdagni, Riccardo; Azria, David; Farcy Jacquet, Marie-Pierre; Chang-Claude, Jenny; Seibold, Petra; West, Catharine; Janelsins, Michelle; Chen, Yuhchyau; Messing, Edward; Morrow, Gary.
Afiliación
  • Kerns SL; Department of Radiation Oncology, University of Rochester Medical Center, Rochester, United States. Electronic address: sarah_kerns@urmc.rochester.edu.
  • Amidon Morlang A; Department of Radiation Oncology, University of Rochester Medical Center, Rochester, United States.
  • Lee SM; Department of Radiation Oncology, University of Rochester Medical Center, Rochester, United States.
  • Peterson DR; Department of Biostatistics and Computational Biology, University of Rochester Medical Center, Rochester, United States.
  • Marples B; Department of Radiation Oncology, University of Rochester Medical Center, Rochester, United States.
  • Zhang H; Department of Radiation Oncology, University of Rochester Medical Center, Rochester, United States.
  • Bylund K; Department of Radiation Oncology, University of Rochester Medical Center, Rochester, United States.
  • Rosenzweig D; Department of Radiation Oncology, University of Rochester Medical Center, Rochester, United States.
  • Hall W; Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, United States.
  • De Ruyck K; Department of Radiation Oncology, Ghent University Hospital and Department of Human Structure and Repair, Ghent University, Ghent, Belgium.
  • Rosenstein BS; Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, United States; Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, United States.
  • Stock RG; Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, United States.
  • Gómez-Caamaño A; Department of Radiation Oncology, Complexo Hospitalario Universitario de Santiago, SERGAS, Santiago de Compostela, Spain; Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), Santiago de Compostela, Spain.
  • Vega A; Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), Santiago de Compostela, Spain; Fundación Pública Galega de Medicina Xenómica-Servizo Galego de Saude (SERGAS), Santiago de Compostela, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Santiago de C
  • Sosa-Fajardo P; Department of Radiation Oncology, Complexo Hospitalario Universitario de Santiago, SERGAS, Santiago de Compostela, Spain; Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), Santiago de Compostela, Spain; Fundación Pública Galega de Medicina Xenómica-Servizo Galego de Saude (SERGA
  • Taboada-Valladares B; Department of Radiation Oncology, Complexo Hospitalario Universitario de Santiago, SERGAS, Santiago de Compostela, Spain; Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), Santiago de Compostela, Spain.
  • Aguado-Barrera ME; Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), Santiago de Compostela, Spain; Fundación Pública Galega de Medicina Xenómica-Servizo Galego de Saude (SERGAS), Santiago de Compostela, Spain.
  • Parker C; Department of Uro-oncology, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, Sutton, United Kingdom.
  • Veldeman L; Department of Radiation Oncology, Ghent University Hospital and Department of Human Structure and Repair, Ghent University, Ghent, Belgium.
  • Fonteyne V; Department of Radiation Oncology, Ghent University Hospital and Department of Human Structure and Repair, Ghent University, Ghent, Belgium.
  • Bultijnck R; Department of Radiation Oncology, Ghent University Hospital and Department of Human Structure and Repair, Ghent University, Ghent, Belgium.
  • Talbot CJ; Leicester Cancer Research Centre, University of Leicester, United Kingdom.
  • Symonds RP; Leicester Cancer Research Centre, University of Leicester, United Kingdom.
  • Johnson K; Leicester Cancer Research Centre, University of Leicester, United Kingdom.
  • Rattay T; Leicester Cancer Research Centre, University of Leicester, United Kingdom.
  • Webb A; Department of Genetics and Genome Biology, University of Leicester, United Kingdom.
  • Lambrecht M; KU Leuven, Radiation Oncology, Leuven, Belgium.
  • de Ruysscher D; KU Leuven, Radiation Oncology, Leuven, Belgium; Maastricht University Medical Center, Department of Radiation Oncology (Maastro Clinic), GROW School for Oncology and Developmental Biology, Maastricht, the Netherlands.
  • Vanneste B; KU Leuven, Radiation Oncology, Leuven, Belgium; Maastricht University Medical Center, Department of Radiation Oncology (Maastro Clinic), GROW School for Oncology and Developmental Biology, Maastricht, the Netherlands.
  • Choudhury A; Division of Cancer Sciences, the University of Manchester, Manchester Academic Health Science Centre, Christie Hospital, Manchester, the Netherlands.
  • Elliott RM; Division of Cancer Sciences, the University of Manchester, Manchester Academic Health Science Centre, Christie Hospital, Manchester, the Netherlands.
  • Sperk E; Department of Radiation Oncology, Universitätsmedizin Mannheim, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.
  • Herskind C; Department of Radiation Oncology, Universitätsmedizin Mannheim, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.
  • Veldwijk MR; Department of Radiation Oncology, Universitätsmedizin Mannheim, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.
  • Rancati T; Prostate Cancer Program, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Avuzzi B; Department of Radiation Oncology 1, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Valdagni R; Prostate Cancer Program, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Department of Radiation Oncology 1, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Department of Oncology and Hemato-oncology, Università degli Studi di Milano, Milan, Italy.
  • Azria D; Department of Radiation Oncology, Montpellier Cancer Institute, Université Montpellier, Inserm U1194, France.
  • Farcy Jacquet MP; ICG Cancer Institute, Centre Hospitalier Universitaire de Nîmes, Nimes, France.
  • Chang-Claude J; Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany; Cancer Epidemiology Group, University Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Germany.
  • Seibold P; Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • West C; Division of Cancer Sciences, the University of Manchester, Manchester Academic Health Science Centre, Christie Hospital, Manchester, the Netherlands.
  • Janelsins M; Department of Surgery, University of Rochester Medical Center, Rochester, United States.
  • Chen Y; Department of Radiation Oncology, University of Rochester Medical Center, Rochester, United States.
  • Messing E; Department of Urology, University of Rochester Medical Center, Rochester, United States.
  • Morrow G; Department of Surgery, University of Rochester Medical Center, Rochester, United States.
Radiother Oncol ; 168: 75-82, 2022 03.
Article en En | MEDLINE | ID: mdl-35077710
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Inhibidores de la Enzima Convertidora de Angiotensina Tipo de estudio: Clinical_trials / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans / Male Idioma: En Revista: Radiother Oncol Año: 2022 Tipo del documento: Article
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Inhibidores de la Enzima Convertidora de Angiotensina Tipo de estudio: Clinical_trials / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans / Male Idioma: En Revista: Radiother Oncol Año: 2022 Tipo del documento: Article